Maitre Michel, Klein Christian, Mensah-Nyagan Ayikoe G
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000, Strasbourg, France.
Alzheimers Res Ther. 2016 Sep 6;8(1):37. doi: 10.1186/s13195-016-0205-y.
Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These effects allow sedation, stress/anxiety reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, Xyrem(R) promotes the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models. Altogether, these data represent additional evidence to suggest that Xyrem(R) may be tested during repeated short periods in populations at risk for Alzheimer's disease.
γ-羟基丁酸（GHB或羟丁酸钠）常用于人类的多种临床适应症，包括麻醉、发作性睡病/猝倒症以及酒精戒断症状。治疗剂量的羟丁酸钠在大脑中诱导产生的药理作用通常依赖于γ-氨基丁酸（GABA）能。这些作用包括镇静、减轻压力/焦虑、诱导深度睡眠、减少神经炎症以及神经保护。此外，如实验室动物模型所示，羟丁酸钠可促进关键基因的表达，减少毒性蛋白病变。总之，这些数据提供了更多证据，表明羟丁酸钠可能在阿尔茨海默病高危人群的短时间重复试验中进行测试。
